| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 29th December 2020 | Robert W Duggan | 8,214 | Exercise of in-the-money or at-the-money derivatives securities (usually options) | $7.01 | $57,580.14 |
| 29th December 2020 | Robert W Duggan | 376,065 | Exercise of in-the-money or at-the-money derivatives securities (usually options) | $7.01 | $2,636,215.65 |
| 8th October 2020 | Mitchell E. Levinson | 856 | Exercise of in-the-money or at-the-money derivatives securities (usually options) | $7.01 | $6,000.56 |
| 23rd June 2020 | Maky Zanganeh | 1,193 | Open or private purchase | $10.70 | $12,767.13 |
| 17th June 2020 | Maky Zanganeh | 7,950 | Open or private purchase | $7.01 | $55,729.50 |
| 15th June 2020 | Mitchell E. Levinson | 5,713 | Exercise of in-the-money or at-the-money derivatives securities (usually options) | $7.01 | $40,048.13 |
| 15th June 2020 | Robert W Duggan | 54,761 | Exercise of in-the-money or at-the-money derivatives securities (usually options) | $7.01 | $383,874.61 |
| 15th June 2020 | Mitchell E. Levinson | 127 | Exercise of in-the-money or at-the-money derivatives securities (usually options) | $7.01 | $890.27 |
| 15th June 2020 | Mitchell E. Levinson | 714 | Exercise of in-the-money or at-the-money derivatives securities (usually options) | $7.01 | $5,005.14 |
| 15th June 2020 | Robert W Duggan | 2,507,112 | Exercise of in-the-money or at-the-money derivatives securities (usually options) | $7.01 | $17,574,855.12 |
Pulse Biosciences
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Pulse Biosciences, Inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary Nano-Pulse Stimulation (NPS) technology. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
Ticker: PLSE
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1625101
Employees: 82
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $38 M (0%)
Assets, Current: $39 M (46%)
Property, Plant and Equipment, Net: $3 M (0%)
Other Assets, Noncurrent: $365 Th (-26%)
Assets: $58 M (39%)
Accounts Payable, Current: $1 M (-24%)
Accrued Liabilities, Current: $3 M (0%)
Liabilities, Current: $5 M (9%)
Liabilities: $16 M (43%)
Common Stock, Value, Issued: $25 Th (19%)
Common Stock, Shares, Issued: $25 Th (20%)
Additional Paid in Capital, Common Stock: $188 M (22%)
Retained Earnings (Accumulated Deficit): $146 M (18%)
Stockholders' Equity (Parent): $42 M (0%)
Liabilities and Equity: $58 M (39%)
Research and Development: $6 M (-51%)
General and Administrative Expenses: $5 M (-51%)
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
